Which has stronger valuation and earnings, IMCR or CGON?

Immunocore has higher revenue and earnings than CG Oncology. Immunocore is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunocore $400.02M 3.78 -$35.51M -$0.37 N/A CG Oncology $4.04M 1,400.25 -$160.99M -$2.69 N/A

Is IMCR or CGON more profitable?

Immunocore has a net margin of -4.20% compared to CG Oncology's net margin of -3,602.68%. Immunocore's return on equity of -4.54% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Immunocore -4.20% -4.54% -1.66% CG Oncology -3,602.68% -25.20% -23.98%

Immunocore (IMCR) Competitors

$29.39 +0.30 (+1.03%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$29.40 +0.00 (+0.02%)

As of 10/9/2026 07:30 PM Eastern

Compare

IMCR vs. IOVA, LGND, KNSA, KOD, and CGON

Should you buy Immunocore stock or one of its competitors? Immunocore's main competitors and comparable companies include Iovance Biotherapeutics (IOVA), Ligand Pharmaceuticals (LGND), Kiniksa Pharmaceuticals International (KNSA), Kodiak Sciences (KOD), and CG Oncology (CGON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immunocore compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Immunocore (NASDAQ:IMCR) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Iovance Biotherapeutics currently has a consensus target price of $12.90, indicating a potential downside of 11.76%. Immunocore has a consensus target price of $56.38, indicating a potential upside of 91.82%. Given Immunocore's higher possible upside, analysts clearly believe Immunocore is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.58

Immunocore has higher revenue and earnings than Iovance Biotherapeutics. Immunocore is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	25.13	-$390.98M	-$0.73	N/A
Immunocore	$400.02M	3.78	-$35.51M	-$0.37	N/A

In the previous week, Iovance Biotherapeutics had 8 more articles in the media than Immunocore. MarketBeat recorded 9 mentions for Iovance Biotherapeutics and 1 mentions for Immunocore. Immunocore's average media sentiment score of 0.81 beat Iovance Biotherapeutics' score of 0.54 indicating that Immunocore is being referred to more favorably in the news media.

Company	Overall Sentiment
Iovance Biotherapeutics	Positive
Immunocore	Positive

Iovance Biotherapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 10.1% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Immunocore has a net margin of -4.20% compared to Iovance Biotherapeutics' net margin of -89.11%. Immunocore's return on equity of -4.54% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
Immunocore	-4.20%	-4.54%	-1.66%

Summary

Immunocore beats Iovance Biotherapeutics on 12 of the 17 factors compared between the two stocks.

How does Immunocore compare to Ligand Pharmaceuticals?

Immunocore (NASDAQ:IMCR) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Immunocore has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

Ligand Pharmaceuticals has lower revenue, but higher earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.78	-$35.51M	-$0.37	N/A
Ligand Pharmaceuticals	$268.09M	22.45	$124.45M	$9.35	32.28

In the previous week, Ligand Pharmaceuticals had 5 more articles in the media than Immunocore. MarketBeat recorded 6 mentions for Ligand Pharmaceuticals and 1 mentions for Immunocore. Immunocore's average media sentiment score of 0.81 beat Ligand Pharmaceuticals' score of 0.39 indicating that Immunocore is being referred to more favorably in the media.

Company	Overall Sentiment
Immunocore	Positive
Ligand Pharmaceuticals	Neutral

Immunocore currently has a consensus price target of $56.38, indicating a potential upside of 91.82%. Ligand Pharmaceuticals has a consensus price target of $337.89, indicating a potential upside of 11.95%. Given Immunocore's higher probable upside, research analysts clearly believe Immunocore is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.58
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	3.00

84.5% of Immunocore shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 10.1% of Immunocore shares are owned by company insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ligand Pharmaceuticals has a net margin of 67.88% compared to Immunocore's net margin of -4.20%. Ligand Pharmaceuticals' return on equity of 20.06% beat Immunocore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-4.20%	-4.54%	-1.66%
Ligand Pharmaceuticals	67.88%	20.06%	11.68%

Summary

Ligand Pharmaceuticals beats Immunocore on 12 of the 17 factors compared between the two stocks.

How does Immunocore compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Immunocore (NASDAQ:IMCR) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by insiders. Comparatively, 10.1% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Kiniksa Pharmaceuticals International has a beta of 0.04, meaning that its stock price is 96% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

Kiniksa Pharmaceuticals International presently has a consensus price target of $93.14, indicating a potential upside of 16.75%. Immunocore has a consensus price target of $56.38, indicating a potential upside of 91.82%. Given Immunocore's higher possible upside, analysts clearly believe Immunocore is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.58

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Immunocore's net margin of -4.20%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Immunocore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%
Immunocore	-4.20%	-4.54%	-1.66%

Kiniksa Pharmaceuticals International has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	9.19	$59.01M	$0.97	82.25
Immunocore	$400.02M	3.78	-$35.51M	-$0.37	N/A

In the previous week, Kiniksa Pharmaceuticals International had 1 more articles in the media than Immunocore. MarketBeat recorded 2 mentions for Kiniksa Pharmaceuticals International and 1 mentions for Immunocore. Kiniksa Pharmaceuticals International's average media sentiment score of 0.91 beat Immunocore's score of 0.81 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Overall Sentiment
Kiniksa Pharmaceuticals International	Positive
Immunocore	Positive

Summary

Kiniksa Pharmaceuticals International beats Immunocore on 13 of the 17 factors compared between the two stocks.

How does Immunocore compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and Immunocore (NASDAQ:IMCR) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Kodiak Sciences presently has a consensus price target of $100.43, suggesting a potential upside of 0.56%. Immunocore has a consensus price target of $56.38, suggesting a potential upside of 91.82%. Given Immunocore's higher probable upside, analysts clearly believe Immunocore is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.58

In the previous week, Kodiak Sciences had 4 more articles in the media than Immunocore. MarketBeat recorded 5 mentions for Kodiak Sciences and 1 mentions for Immunocore. Immunocore's average media sentiment score of 0.81 beat Kodiak Sciences' score of 0.32 indicating that Immunocore is being referred to more favorably in the news media.

Company	Overall Sentiment
Kodiak Sciences	Neutral
Immunocore	Positive

Kodiak Sciences has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-273.23%	-85.48%
Immunocore	-4.20%	-4.54%	-1.66%

Immunocore has higher revenue and earnings than Kodiak Sciences. Immunocore is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A
Immunocore	$400.02M	3.78	-$35.51M	-$0.37	N/A

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by company insiders. Comparatively, 10.1% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Kodiak Sciences has a beta of 2.03, suggesting that its stock price is 103% more volatile than the broader market. Comparatively, Immunocore has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

Summary

Immunocore beats Kodiak Sciences on 8 of the 15 factors compared between the two stocks.

How does Immunocore compare to CG Oncology?

Immunocore (NASDAQ:IMCR) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

Immunocore presently has a consensus target price of $56.38, suggesting a potential upside of 91.82%. CG Oncology has a consensus target price of $87.50, suggesting a potential upside of 37.10%. Given Immunocore's higher probable upside, analysts plainly believe Immunocore is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.58
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

84.5% of Immunocore shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 10.1% of Immunocore shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Immunocore has higher revenue and earnings than CG Oncology. Immunocore is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.78	-$35.51M	-$0.37	N/A
CG Oncology	$4.04M	1,400.25	-$160.99M	-$2.69	N/A

Immunocore has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market.

In the previous week, CG Oncology had 1 more articles in the media than Immunocore. MarketBeat recorded 2 mentions for CG Oncology and 1 mentions for Immunocore. CG Oncology's average media sentiment score of 1.25 beat Immunocore's score of 0.81 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Immunocore	Positive
CG Oncology	Positive

Immunocore has a net margin of -4.20% compared to CG Oncology's net margin of -3,602.68%. Immunocore's return on equity of -4.54% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-4.20%	-4.54%	-1.66%
CG Oncology	-3,602.68%	-25.20%	-23.98%

Summary

Immunocore beats CG Oncology on 11 of the 17 factors compared between the two stocks.

Get Immunocore News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMCR vs. The Competition

Export

Metric	Immunocore	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.51B	$3.93B	$7.25B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	-79.43	13.55	275.01	26.14
Price / Sales	3.78	1,209.42	582.85	87.88
Price / Cash	N/A	119.49	76.96	53.71
Price / Book	3.91	17.17	11.22	6.33
Net Income	-$35.51M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-1.08%	-1.34%	-0.89%	-1.40%
1 Month Performance	-9.85%	-8.04%	-4.02%	-3.35%
1 Year Performance	-9.29%	14.18%	7.13%	1.49%

Immunocore Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMCR Immunocore	3.2904 of 5 stars	$29.39 +1.0%	$56.38 +91.8%	-9.3%	$1.51B	$400.02M	N/A	524	News Coverage
IOVA Iovance Biotherapeutics	2.0796 of 5 stars	$13.23 -6.5%	$12.40 -6.2%	+596.2%	$6.01B	$324.97M	N/A	975	Analyst Forecast
LGND Ligand Pharmaceuticals	3.8348 of 5 stars	$297.87 -2.9%	$337.89 +13.4%	+69.8%	$5.95B	$268.09M	31.93	47	Insider Trade
KNSA Kiniksa Pharmaceuticals International	4.0452 of 5 stars	$75.82 -0.6%	$93.14 +22.9%	+110.6%	$5.95B	$840.85M	78.56	366	Analyst Upgrade
KOD Kodiak Sciences	2.6583 of 5 stars	$92.84 -1.0%	$100.43 +8.2%	+741.4%	$5.92B	N/A	N/A	124	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMCR) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunocore (IMCR) Competitors

IMCR vs. IOVA, LGND, KNSA, KOD, and CGON

How does Immunocore compare to Iovance Biotherapeutics?

Summary

How does Immunocore compare to Ligand Pharmaceuticals?

Summary

How does Immunocore compare to Kiniksa Pharmaceuticals International?

Summary

How does Immunocore compare to Kodiak Sciences?

Summary

How does Immunocore compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR vs. The Competition

Immunocore Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunocore (IMCR) Competitors

IMCR vs. IOVA, LGND, KNSA, KOD, and CGON

How does Immunocore compare to Iovance Biotherapeutics?

Do analysts prefer IOVA or IMCR?

Which has preferable valuation and earnings, IOVA or IMCR?

Does the media favor IOVA or IMCR?

Which has more volatility & risk, IOVA or IMCR?

Do institutionals & insiders have more ownership in IOVA or IMCR?

Is IOVA or IMCR more profitable?

Summary

How does Immunocore compare to Ligand Pharmaceuticals?

Which has more risk and volatility, IMCR or LGND?

Which has preferable earnings and valuation, IMCR or LGND?

Does the media refer more to IMCR or LGND?

Do analysts recommend IMCR or LGND?

Do insiders & institutionals have more ownership in IMCR or LGND?

Is IMCR or LGND more profitable?

Summary

How does Immunocore compare to Kiniksa Pharmaceuticals International?

Do insiders and institutionals have more ownership in KNSA or IMCR?

Which has more volatility & risk, KNSA or IMCR?

Do analysts rate KNSA or IMCR?

Is KNSA or IMCR more profitable?

Which has higher earnings and valuation, KNSA or IMCR?

Does the media prefer KNSA or IMCR?

Summary

How does Immunocore compare to Kodiak Sciences?

Do analysts prefer KOD or IMCR?

Does the media prefer KOD or IMCR?

Is KOD or IMCR more profitable?

Which has higher valuation and earnings, KOD or IMCR?

Do institutionals & insiders have more ownership in KOD or IMCR?

Which has more risk & volatility, KOD or IMCR?

Summary

How does Immunocore compare to CG Oncology?

Do analysts prefer IMCR or CGON?

Do institutionals and insiders have more ownership in IMCR or CGON?

Which has stronger valuation and earnings, IMCR or CGON?

Which has more volatility and risk, IMCR or CGON?

Does the media favor IMCR or CGON?

Is IMCR or CGON more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR vs. The Competition

Immunocore Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools